For the year ending 2025-12-31, SGP had $80,090K increase in cash & cash equivalents over the period. -$33,490K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -39,869 |
| Depreciation expense | 612 |
| Loss on disposal of property and equipment | -5 |
| Non-cash lease expense | 383 |
| Gain on lease termination | 518 |
| Stock-based compensation | 2,786 |
| Change in fair value of redeemable convertible preferred stock tranche liability | 1,526 |
| Interest receivable | 74 |
| Other receivables | 8 |
| Prepaid expenses and other current assets | 186 |
| Other non-current assets | 38 |
| Accounts payable | 549 |
| Payroll-related accruals | 900 |
| Accrued expenses and other current liabilities | 1,672 |
| Lease liability | -441 |
| Net cash used in operating activities | -32,701 |
| Property and equipment | 789 |
| Purchases of short-term investments | 17,001 |
| Redemptions of short-term investments | 5,996 |
| Net cash (used in) provided by investing activities | -11,794 |
| Proceeds from exercise of stock options | 170 |
| Repurchases of common stock | 1,450 |
| Gross proceeds from issuance of redeemable convertible preferred stock | 127,336 |
| Issuance costs of redeemable convertible preferred stock | 288 |
| Payments for deferred offering cost | 1,183 |
| Net cash provided by financing activities | 124,585 |
| Net increase in cash and cash equivalents | 80,090 |
| Cash and cash equivalents, beginning of year | 16,268 |
| Cash and cash equivalents, end of year | 96,358 |
SpyGlass Pharma, Inc. (SGP)
SpyGlass Pharma, Inc. (SGP)